Tuesday, October 30, 2018 5:48:00 PM
- Priced below Consensi Approval & NT219 Ownership
- Priced at FDA refuted Consensi data falsification allegations on July'17
- Lowest RSI ever (oversold)
- Consensi: $2.40/sh for China + Korea
- Consensi: $3.94/sh for US + CA -> $6.79/sh Total
- Changshan paid $1M (May'18) and will pay additional $2.5M for short CFDA regulatory and up to $6M for commercial milestones
- Changshan in CFDA process, which is a formality having FDA approval lately
- Changshan & Korea 12% Net Royalties, same expected for US
- Awaiting deal with US pharma
- 2018-06-01 Annual offering 3.26M @ $2.50/ads (still)
- 2018-06-19 HC Wainwright last Buy PT $12.50/sh
(SeaOfSand and I keep tracking, should bounce)
Daily
Evaluation (nothing changes)
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM